Skip to main content

Table 3 Meta-regression

From: Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis

  OR rate CR rate RR
Study (n) R2 (%) p-value Study (n) R2 (%) P-value Study (n) R2 (%) p-value
Sample size 37 5.11 0.1079 37 1.29 0.2262 32 0.00 0.7044
Year of publication 37 0.00 0.3522 37 5.83 0.0905 32 0.00 0.9247
Age 30 23.29 0.0103 30 45.37 < 0.0001 27 0.00 0.3689
Proportion of male 30 0.00 0.6095 30 0.00 0.5294 27 0.00 0.4814
Evaluation time 29 3.70 0.2370 29 0.00 0.4967 27 0.00 0.6003
Follow-up time 37 8.59 0.1167 37 0.00 0.9396 32 0.00 0.6639
Quality score 37 0.00 0.1886 37 0.10 0.3369 32 0.42 0.3695